Clinical Trials Browser

OTHER × Denosumab × Breast × Clear all

NCT06374459 2026-02-09

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Phase 1/2 Recruiting

Breast Neoplasms

NCT02051218 2025-12-30

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

Phase 3 Active not recruiting

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT04549207 2025-11-28

Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer

Phase 4 Active not recruiting

Breast Neoplasms

NCT04067726 2025-10-16

TRIDENT

Phase 2 Active not recruiting

Breast Neoplasms

NCT04711109 2025-04-02

BRCA-P

Phase 3 Active not recruiting

Breast Diseases, Breast Neoplasms, Neoplasms

NCT03629717 2024-10-16

RANKL Inhibition and Breast Tissue Biomarkers

Phase EARLY_PHASE1 Completed

Breast Neoplasms

NCT03324932 2023-10-06

Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer

Phase 3 Active not recruiting

Breast Neoplasms

NCT02366130 2021-10-07

Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer

Phase 2 Completed

45 enrolled 7 charts

Breast Neoplasms

NCT02682693 2021-02-02

GeparX

Phase 2 Completed

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT02900469 2020-08-21

Presurgical Trial of Denosumab in Breast Cancer

Phase EARLY_PHASE1 Completed

Breast Neoplasms

NCT01952054 2019-11-22

Denosumab for Breast Cancer With Bone Mets

Phase 2 Terminated

7 enrolled 8 charts

Breast Neoplasms

NCT03811509 2019-01-28

B-ABLE

Phase 4 Unknown

Breast Neoplasms, Osteoporosis, Arthralgia, Osteoporotic Fractures, Musculoskeletal Pain

NCT01864798 2018-11-27

D-Beyond

Phase 2 Terminated

Breast Neoplasms

NCT03070002 2018-11-20

Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells

Phase 2 Terminated

1 enrolled 6 charts

Breast Neoplasms, Neoplastic Cells, Circulating